Table 1.
Baseline characteristics of the study population (n = 46)
| Characteristics | Mild n = 25 |
Moderate n = 5 |
Severe n = 16 |
Total N = 46 |
|---|---|---|---|---|
| Age (years), median [IQR] | 60 [50, 72] | 42 [37, 50] | 71 [62, 77] | 68 [56, 74] |
| ≤40 | 6 | 1 | 1 | 8 |
| 41–60 | 5 | 2 | 2 | 9 |
| 61–80 | 12 | 1 | 10 | 23 |
| 81–90 | 2 | 1 | 3 | 6 |
| Sex | ||||
| Male | 8 | 2 | 12 | 22 |
| Female | 17 | 3 | 4 | 24 |
| Comorbidities | ||||
| Cardiovascular disease | 5 | 2 | 9 | 16 |
| Endocrine disease | 4 | 2 | 5 | 11 |
| Digestive disease | 2 | 6 | 8 | |
| Respiratory disease | 1 | 2 | 3 | |
| Malignancy | 1 | 1 | 2 | |
| Allergy | 1 | 1 | ||
| Muscular skeletal disease | 3 | 1 | 3 | 7 |
| Vaccine brand | ||||
| AZD1222 | 16 | 3 | 14 | 33 |
| BNT162b2 | 6 | 2 | 1 | 9 |
| JNJ-78436735 | 2 | 1 | 3 | |
| AZD1222 + BNT162b2 | 1 | 1 | ||
| Number of vaccinations | ||||
| Dose 1 | 18 | 9 | 9 | 36 |
| Dose 2 | 7 | 1 | 2 | 10 |
| Symptom onset after vaccination (days), median [IQR] | 1 [1,1] | 1 [1,2] | 1 [1, 1] | 1 [1, 1] |
| 1 | 22 | 3 | 15 | 40 |
| 2 | 2 | 2 | 4 | |
| 3 | 1 | 1 | 2 |
IQR, interquartile range.